ArticleArchives of medical science : AMS2024
Pepsinogen I, pepsinogen II, gastrin-17, and
Article in Archives of medical science : AMS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Gastric Mucosa Cancer Risk: The Operative Link on Gastritis Assessment Staging System.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- The Role of Serum Pepsinogen Tests for Detecting Gastric Cancer Between Sexes and Among Age Groups.Gut and liver · 2026Review
- The causal effects of 1400 genetically determined human blood metabolites and metabolite ratios on the risk of gastrointestinal tumors: a Mendelian randomization study.Archives of medical science : AMS · 2026Article
- Global research trends on the association between gastric cancer and chronic atrophic gastritis: a bibliometric analysis.Discover oncology · 2025Article
- Association between serum gastric biomarkers and metabolic syndrome.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Article
- Assessing Serum Pepsinogen andCancers · 2025Article
- Screening for and surveillance of premalignant conditions of the stomach.Best practice & research. Clinical gastroenterology · 2025Review
- Point-of-Care Diagnosis of Atrophic Gastritis by Serological Biomarker Test (GastroPanelJournal of clinical medicine · 2025Article
- Hp eradication decreased the expression level of PG II in patients of Hp negative with gastric intestinal metaplasia: a retrospective cross-sectional study.Journal of health, population, and nutrition · 2025Article
- Effects of a combination of bifidobacteria quadruple viable bacteria tablets and quadruple therapy on inflammatory response andFrontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Atrophic gastritis and intestinal metaplasia are precursor lesions of gastric cancer. The aim of this study was to determine the usefulness of the biomarkers pepsinogen I(PgI), pepsinogen II (PgII), gastrin-17, and Methods: We studied 129 patients with gastric symptoms. The biomarker status was determined using GastroPanel by means of the ELISA-technique. Results: Biomarkers detected atrophy in 14% of the subjects, and 49.6% had positive antibodies for Conclusions: In the Western Mexican population, precursor lesions (AG, IM) are common in adults (45%) with dyspepsia but infrequent in children (8%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.